What M33 Growth does

M33 Growth is a Boston-based venture and growth-stage investment firm that partners with bootstrapped entrepreneurs in North American B2B software and healthcare services to accelerate growth through concentrated capital and hands-on operating support. Founded in 2017-2018 by Mike Anello and Gabe Ling (with Brian Shortsleeve), the firm invests $10-40 million per company and takes meaningful ownership positions, offering both primary capital for growth and secondary capital for shareholder liquidity. M33 deliberately limits its active-lead portfolio to approximately 19 companies — its next investment will be company #19 — under the "Mach 33 / Escape Velocity" branding, asserting that concentration produces deeper engagement than diversified growth funds.

The firm's operating model rests on four core competency pillars — Go-To-Market execution, Strategy, M&A advisory, and Talent — delivered through an in-house team supplemented by named Growth Acceleration Specialists (covering Product/AI, Engineering/AI, Data-centric AI, Marketing, and Post Sale) and a 12-person advisor ecosystem. In recent years M33 has added a proprietary "AI Execution" framework aimed at helping portfolio companies re-imagine products, optimize pricing, and deploy AI-powered sales execution, positioning the firm as an early mover in AI-enabled value creation for B2B software. The portfolio spans vertical software and tech-enabled services (Apogee Interactive, BeSmartee, BFC Software, Clear Demand, GoDocs, Leading2Lean, O3 Solutions, Operix, PerformLine, Rosnet, SmartKargo, Swift Comply, Thanx, Total Synergy, YAPI), healthcare services (Luke, Pediatrica Health Group, U.S. Neurology Associates, The Oncology Institute of Hope & Innovation — the latter taken public on NASDAQ as TOI), and infrastructure/EPC software (ARES PRISM, Titan Cloud, W Energy). M33 Growth closed a $260 million second fund in February 2020.

The business model is classic closed-end growth equity: management fees on committed/invested capital and carried interest on realized exits. Revenue is not publicly disclosed; the firm is privately held as M33 Growth LLC. Sourcing is direct and referral-driven — outbound to bootstrapped founders, inbound via the "Strike Zone" criteria page and C-Suite Resource Center content marketing, plus referrals from the advisor network and prior founders. Co-investment relationships with Charlesbank Capital Partners, True Wind Capital, Roca Partners, Havencrest, Ribbit Capital, and RHI Group indicate a developed syndication network that supplements Fund II's $260M of primary capital.

Name

M33 Growth

Legal name

M33 Growth LLC

Website

https://m33growth.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

M33 Growth is a Boston-based growth equity firm founded in 2017-2018 that invests $10-40 million per company in bootstrapped North American B2B software and healthcare services businesses, providing capital plus hands-on operating support across GTM, Strategy, M&A, Talent, and AI Execution across a concentrated portfolio of approximately 19 companies.

Ownership category

akta.pro rank

Product category

Growth Equity / Venture Capital

NAICS

Portfolio Management and Investment Advice (52394), Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

Technology & Software Growth Equity (FSANACAA)

akta.pro secondary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Growth equity investing
• Venture capital partnerships
• Private equity management
• Portfolio company support
• Bootstrap company funding

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Investment Management: M33 Growth generates returns through equity investments in bootstrapped B2B software and healthcare companies. Their revenue comes from management fees and carried interest on fund returns. They invest $10-40M per company and provide both primary capital for growth and secondary capital for shareholder liquidity.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

M33 Growth is a venture and growth stage investment firm that partners with bootstrapped entrepreneurs in B2B software and healthcare by providing both primary growth capital ($10–40M per company) and secondary capital for shareholder liquidity. Beyond capital, the firm delivers hands-on operational support across four core areas — Go-To-Market execution, Strategy, M&A, and Talent — augmented by a proprietary AI Execution capability for portfolio companies.

Product overview

M33 Growth is a growth equity firm that provides capital and operational resources to bootstrapped B2B software and healthcare companies. Rather than offering a traditional SaaS product, the firm provides investment services alongside four core operational capabilities: Go-To-Market execution, Strategy, M&A advisory, and Talent acquisition. The firm also offers AI Execution advisory services to help portfolio companies integrate AI capabilities into their products and operations.

Differentiator

Problem solved

Functional benefit

Products and services

• B2B Software Growth Equity Growth equity investment program targeting bootstrapped or minimally capitalized B2B software companies with $5M+ ARR, 20%+ organic growth, and 90%+ gross retention. M33 deploys $10–40M per company and takes a meaningful ownership stake.
• Healthcare Services Growth Equity Growth equity investment program for bootstrapped U.S. healthcare services companies with $15M+ revenue or $2M+ EBITDA that demonstrate better patient outcomes at lower cost through patient-first clinical models.
• Secondary Capital for Shareholder Liquidity Secondary capital structure within M33 Growth's investments that allows founders and existing shareholders to partially monetize their stakes while retaining meaningful upside in the company.
• GTM Execution Support Hands-on go-to-market execution support delivered to portfolio companies by M33 Growth's team and growth acceleration specialists, covering sales leadership, demand generation, and pricing.
• M&A Advisory and Execution Strategic M&A advisory and execution support for portfolio companies, including acquisition sourcing, deal execution, and integration guidance, delivered by M33 Growth's Platforms & Strategic M&A leadership.
• Talent Acquisition and Development Talent acquisition and executive development support for portfolio companies, led by M33 Growth's Head of Talent and supported by an ecosystem of operating advisors.
• AI Execution Advisory

Named customers18 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Five Elms Capital: Kansas City-based growth equity firm investing $10–$50M in profitable, founder-led B2B software companies. Closely matched check size and bootstrapped-software thesis to M33.
• Mainsail Partners: Growth equity firm focused exclusively on bootstrapped, founder-led B2B software companies. Highly comparable thesis around capital-efficient SaaS investing with operational value-add.
• Volition Capital: Boston-based growth equity firm investing in bootstrapped, profitable B2B software and tech-enabled services companies with $5M–$50M of revenue. Most direct comparable given shared geography, founder-friendly positioning, and concentrated portfolio approach.
• Susquehanna Growth Equity: Growth equity arm of Susquehanna International Group, investing in bootstrapped and capital-efficient B2B software and services. Comparable ticket sizes and founder-friendly positioning.
• Peak Equity Partners: Growth equity firm focused on bootstrapped, profitable B2B software and technology-enabled services companies. Similar investment criteria around ARR thresholds and gross retention.
• Trivest Partners: Growth-oriented PE firm investing in founder-led businesses with $5M–$50M EBITDA across B2B services and software. Comparable thesis around partnership-oriented, non-extractive capital.

Broad incumbents

• Summit Partners: Boston-headquartered growth equity firm investing across technology, healthcare, and growth-stage companies. Overlap with M33 in B2B software and healthcare but operates at much larger AUM and check sizes.
• TA Associates: Boston-based growth equity firm with substantial software and healthcare investing practice. Broader incumbent competitor for B2B SaaS and healthcare services deals, but operates at meaningfully larger fund size.
• Insight Partners: Large growth-stage investor in B2B software with strong value-add operating model and AI focus. Comparable in operating-partner approach but at vastly greater AUM and stage range.

Regional players

• Riverside Partners: Boston-based private equity firm investing in healthcare and technology-enabled services. Overlap with M33's healthcare thesis and Boston footprint, though typically at smaller scale and different stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments18 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about M33 Growth